Waters Unveils Two Next-Generation Mass Spectrometers at ASMS 2026, Setting New Benchmarks for Multiomics and Structural Biology
核心洞察
Waters Corporation (搜索) launched the Xevo MRT P10 MS, delivering up to 20x improvement in MS/MS sensitivity and identifying up to 40% more lipids than leading alternative benchtop HRMS systems.
The Cyclic IMS P20 MS was also introduced, featuring a greater than 10-fold increase in MS/MS sensitivity and a 50% extended upper mass range for advanced structural and spatial omics.
Both platforms integrate DESI XS and/or MALDI XS imaging sources, enabling high-resolution spatial analysis down to the cellular level for deeper disease understanding.
Waters Corporation (搜索) introduced two groundbreaking mass spectrometry platforms at the 74th ASMS Conference on Mass Spectrometry and Allied Topics, each designed to push the boundaries of sensitivity, speed, and structural resolution in multiomics and biopharmaceutical research. The Xevo MRT P10 Mass Spectrometer and the Cyclic IMS P20 Mass Spectrometer represent the company's new "Premium" performance tier, targeting high-throughput laboratories engaged in biomarker discovery, drug development, and disease pathway elucidation.
Xevo MRT P10 MS: Redefining Benchtop High-Resolution Mass Spectrometry
The Xevo MRT P10 MS, a high-resolution Quadrupole Time-of-Flight (QToF) system, delivers up to a 20-fold improvement in MS/MS sensitivity compared to its predecessor, according to internal Waters testing. This leap in sensitivity enables scientists to detect low-abundance compounds in complex biological samples with greater confidence. The system also doubles acquisition speeds relative to the prior-generation Xevo MRT, making it the fastest benchtop HRMS platform commercially available as of April 2026.
"With the Xevo MRT P10 MS, we are raising the standard for benchtop high-resolution mass spectrometry," said James Hallam, Vice President & General Manager, Liquid Chromatography-Mass Spectrometry, Waters Analytical Sciences, Waters Corporation (搜索). "By combining enhanced MS/MS sensitivity, the industry's fastest benchtop acquisition speeds, and advanced intelligent acquisition modes in LC-MS/MS — and layering in a new benchmark for MS imaging speed and throughput with our DESI XS — this platform empowers researchers to see more biology, accelerate discovery, and make confident decisions."
In comparative lipid profiling by LC-MS/MS, the Xevo MRT P10 MS enabled identification of up to 40% more lipids than the most competitive alternative benchtop high-resolution system. This enhancement supports more comprehensive biological interpretation in lipidomics research and deepens disease understanding. The platform also supports high-throughput, deep proteome discovery by combining greater sensitivity with ultra-fast acquisition rates and advanced acquisition modes, allowing confident detection of low-abundance peptides and comprehensive protein identification at scale.
When paired with the DESI XS ion source, the Xevo MRT P10 MS unlocks rapid spatial analysis down to the cellular level at up to 200 Hz, increasing throughput six-fold while preserving image quality. This represents up to a 2x improvement in imaging speed compared to the current Waters Xevo MRT MS with DESI XS, and up to 4x imaging speed compared to the next-best competitive MS imaging system.
Corey Broeckling, Ph.D., Director of the Bioanalysis and Omics Center at Colorado State University, noted: "As a core research facility, we must be prepared to respond to challenging and often unexpected client requests, many of which relate to research into complex diseases. We leverage the exceptional MS/MS sensitivity and fast acquisition rates of the Xevo MRT P10 MS for multiomics research. Its excellent resolution enables us to separate signals of similar mass at very high acquisition speeds, delivering deep, high-quality coverage while maintaining sub-ppm mass accuracy."
The Xevo MRT P10 MS is expected to be available globally beginning summer 2026.
Cyclic IMS P20 MS: A New Benchmark in Structural and Spatial Omics
The Cyclic IMS P20 Mass Spectrometer combines multipass Cyclic Ion Mobility Spectrometry with an expanded suite of fragmentation, probing, and imaging capabilities. The system delivers a greater than 10-fold increase in MS/MS sensitivity compared to its predecessor, alongside an upper mass range extended by more than 50% to over 100 kDa.
"Waters recognizes that advanced tools for structural and spatial omics play a critical role in delivering therapeutic breakthroughs," said Hallam. "With its powerful fusion of capabilities, the Cyclic IMS P20 MS delivers a previously unattainable view into subtle molecular differences, unlocking a new level of understanding of the mechanisms that drive disease and advancing next-generation discovery."
The platform integrates complementary structural probing approaches including tandem ion mobility spectrometry (IMSn), electron-capture dissociation (ECD), surface-induced dissociation (SID), and collision-induced unfolding (CIU), delivering what Waters describes as the most comprehensive spatial and structural molecular view within a single platform.
Kostas Thalassinos, Ph.D., Professor of Mass Spectrometry and Academic Lead at the Institute of Structural and Molecular Biology, University College London, highlighted the system's impact on disease research: "My lab studies proteins involved in misfoldings that drive human disease, which are notoriously difficult to characterize. The increase in sensitivity delivered by the new functionality is truly remarkable. It stands to significantly accelerate our analyses, potentially by an order of magnitude, and enables us to probe critical low-abundance species in far greater detail. These rare molecular populations are essential for delineating the mechanisms that drive human disease."
The Cyclic IMS P20 MS also pioneers the combination of Matrix-Assisted Laser Desorption/Ionization (MALDI) and Desorption Electrospray Ionization (DESI) imaging sources with advanced multipass cyclic ion mobility and IMS separation. This integrated approach broadens coverage across small molecules, lipids, peptides, and proteins, while separating isobaric and stereoisomeric compounds. The resulting multi-dimensional molecular maps support biomarker identification directly from tissue and provide increased confidence in lipidomics, drug and metabolite localization, and translational research.
The Cyclic IMS P20 MS is expected to be available globally beginning September 2026.